Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher

The medical center is at the forefront of research in interstitial lung disease associated with systemic connective tissue diseases and hypersensitivity. The focus is on evaluating the efficacy of novel therapies like pirfenidone and nintedanib, aiming to improve patient outcomes and quality of life.

• Systemic Connective Tissue Disease
• Hypersensitivity Pneumonitis

Through rigorous clinical trials, the center is advancing the understanding of these complex conditions, contributing to the development of more effective treatment protocols.

Specializing in Systemic Lupus Erythematosus, the center conducts extensive research to assess the safety and efficacy of innovative treatments like ESK-001 and deucravacitinib. These studies aim to enhance disease management and patient care.

• British Isles Lupus Assessment Group (BILAG)
• Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)

The center's work is pivotal in developing new therapeutic strategies that address the diverse manifestations of SLE.

Research at the center includes a focus on psoriatic arthritis and axial spondyloarthritis, with studies on treatments like secukinumab and filgotinib. These efforts aim to improve long-term safety and efficacy in managing these chronic conditions.

• Chronic Plaque Psoriasis
• Ankylosing Spondylitis

By exploring new treatment avenues, the center is enhancing therapeutic options for patients with these debilitating diseases.

The center is pioneering research in knee osteoarthritis, focusing on the regenerative potential of treatments like RHH646. This research aims to provide innovative solutions for cartilage repair and pain management.

• Articular Cartilage Regeneration
• Long-term Safety and Tolerability

These studies are crucial in developing therapies that can significantly improve the quality of life for osteoarthritis patients.

Focusing on polymyalgia rheumatica, the center evaluates the efficacy of secukinumab in combination with glucocorticoid taper regimens. This research is vital for advancing treatment strategies for patients experiencing relapses.

• Glucocorticoid Taper Regimen
• Sustained Remission

The center's work is instrumental in refining therapeutic approaches to achieve better patient outcomes.

In the field of atrial fibrillation, the center is investigating the efficacy of abelacimab in reducing the risk of ischemic stroke. This research is crucial for patients unsuitable for traditional oral anticoagulation therapy.

• Ischemic Stroke Prevention
• Anticoagulation Alternatives

Through these studies, the center is contributing to safer and more effective management of atrial fibrillation.

The center is advancing research in dermatomyositis and polymyositis, focusing on treatments like enpatoran and brepocitinib. These studies aim to improve muscle function and reduce disease activity.

• American College of Rheumatology (ACR) Criteria
• European League Against Rheumatism (EULAR) Criteria

By exploring new therapeutic options, the center is enhancing care for patients with these inflammatory myopathies.

Research at the center includes a focus on IgG4-related disease, with studies on the effects of obexelimab. This research is essential for understanding and managing disease flares effectively.

• Glucocorticoid Therapy
• Long-term Safety and Tolerability

The center's work is pivotal in developing targeted therapies for this complex condition.

The center is at the forefront of research in gout and hyperuricemia, evaluating the efficacy of tigulixostat compared to allopurinol. This research aims to optimize uric acid management and improve patient outcomes.

• Uric Acid Reduction
• Comparative Efficacy Studies

Through these studies, the center is enhancing therapeutic strategies for managing gout effectively.

Specializing in Sjögren's syndrome, the center conducts research on treatments like deucravacitinib and efgartigimod. These studies focus on improving disease activity and long-term safety.

• ESSDAI Improvement
• Long-term Safety Studies

The center's work is crucial in developing effective management strategies for this autoimmune condition.

Research at the center includes a focus on giant cell arteritis, comparing the efficacy of etanercept and methotrexate. This research is vital for achieving steroid-free remission in patients.

• Steroid-free Remission
• Comparative Treatment Efficacy

Through these studies, the center is enhancing therapeutic options for managing giant cell arteritis.

The center is pioneering research in androgenetic alopecia, focusing on the efficacy and safety of clascoterone solution. This research aims to provide innovative solutions for hair loss management.

• Hair Regrowth Efficacy
• Safety and Tolerability

These studies are crucial in developing therapies that can significantly improve the quality of life for patients with hair loss.